AR080541A1 - Tratamiento para la endometriosis - Google Patents
Tratamiento para la endometriosisInfo
- Publication number
- AR080541A1 AR080541A1 ARP100102257A ARP100102257A AR080541A1 AR 080541 A1 AR080541 A1 AR 080541A1 AR P100102257 A ARP100102257 A AR P100102257A AR P100102257 A ARP100102257 A AR P100102257A AR 080541 A1 AR080541 A1 AR 080541A1
- Authority
- AR
- Argentina
- Prior art keywords
- quinagolide
- treatment
- endometriosis
- micrograms
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Una composicion farmacéutica que comprende quinagolida para el tratamiento y/o la prevencion de la endometriosis, en donde la composicion es para administracion en una dosis de 15 a 39 microgramos de quinagolida/día durante 10 a 20 días; seguida de administracion en una dosis 40 a 64 microgramos de quinagolida/día durante otros 10 a 20 días; seguida de la administracion en una dosis de 65 a 85 microgramos de quinagolida/día durante por lo menos 2 meses. Reivindicacion 4: Una composicion para uso de acuerdo con cualquier reivindicacion precedente para el tratamiento o la prevencion de la endometriosis en un sujeto que tiene, o que tiene tendencia a la, hiperprolactinemia. Reivindicacion 15: Una composicion farmacéutica que comprende quinagolida para el tratamiento y/o la prevencion del cáncer reproductivo. Reivindicacion 17: Una composicion farmacéutica que comprende quinagolida para el tratamiento de la infertilidad en un paciente que tiene endometriosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09251652 | 2009-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080541A1 true AR080541A1 (es) | 2012-04-18 |
Family
ID=41278682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102257A AR080541A1 (es) | 2009-06-26 | 2010-06-25 | Tratamiento para la endometriosis |
Country Status (7)
Country | Link |
---|---|
US (2) | US20120157489A1 (es) |
EP (1) | EP2445501A2 (es) |
JP (1) | JP5968781B2 (es) |
AR (1) | AR080541A1 (es) |
CA (1) | CA2765997A1 (es) |
TW (1) | TW201102066A (es) |
WO (1) | WO2010150098A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SA08290041B1 (ar) * | 2007-02-01 | 2012-06-05 | فيرينج انترناشونال سنتر اس آيه | أدوية من أجل معالجة بطانة الرحم |
EP3017809A1 (en) | 2014-11-07 | 2016-05-11 | Ferring B.V. | Drug-device unit containing quinagolide |
WO2023031218A1 (en) | 2021-08-31 | 2023-03-09 | Ferring B.V. | Diagnosis and treatment of ectopic endometriosis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1534289B2 (en) * | 2002-08-30 | 2012-02-22 | Kyowa Hakko Kogyo Co., Ltd. | Adenosine a2a receptor antagonists for treating restless legs syndrome or nocturnal myoclonus |
SA08290041B1 (ar) * | 2007-02-01 | 2012-06-05 | فيرينج انترناشونال سنتر اس آيه | أدوية من أجل معالجة بطانة الرحم |
-
2010
- 2010-06-25 TW TW099120796A patent/TW201102066A/zh unknown
- 2010-06-25 US US13/380,098 patent/US20120157489A1/en not_active Abandoned
- 2010-06-25 AR ARP100102257A patent/AR080541A1/es unknown
- 2010-06-25 EP EP10740269A patent/EP2445501A2/en not_active Withdrawn
- 2010-06-25 WO PCT/IB2010/001687 patent/WO2010150098A2/en active Application Filing
- 2010-06-25 JP JP2012516881A patent/JP5968781B2/ja active Active
- 2010-06-25 CA CA2765997A patent/CA2765997A1/en not_active Abandoned
-
2013
- 2013-08-07 US US13/961,027 patent/US20140194460A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2445501A2 (en) | 2012-05-02 |
TW201102066A (en) | 2011-01-16 |
WO2010150098A2 (en) | 2010-12-29 |
US20120157489A1 (en) | 2012-06-21 |
JP2012530776A (ja) | 2012-12-06 |
JP5968781B2 (ja) | 2016-08-10 |
CA2765997A1 (en) | 2010-12-29 |
WO2010150098A3 (en) | 2011-05-12 |
US20140194460A1 (en) | 2014-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
NZ588913A (en) | Liver cancer drug | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
CL2008001855A1 (es) | Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa. | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
PE20120713A1 (es) | Composiciones sublinguales de dexmedetomidina y metodos para su uso | |
CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
EA201290833A1 (ru) | Применение амисульприда в качестве противорвотного средства | |
PE20061314A1 (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide | |
UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
AR080541A1 (es) | Tratamiento para la endometriosis | |
AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |